<?xml version="1.0" encoding="UTF-8"?>
<p id="para350">The handful of articles published on vaccine research and development costs to date are either too descriptive or based on expert opinions with little data input to validate those claims,
 <xref rid="bib16" ref-type="bibr">16</xref>, 
 <xref rid="bib28" ref-type="bibr">28</xref>, 
 <xref rid="bib35" ref-type="bibr">35</xref> focusing on single pathogens
 <xref rid="bib15" ref-type="bibr">
  <sup>15</sup>
 </xref> or only on clinical research and development phases.
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib28" ref-type="bibr">28</xref> Studies
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib36" ref-type="bibr">36</xref>—one drawing on source data and assumptions from the other—have attempted to overcome several of the above limitations, focusing their analyses on either poverty diseases or epidemic infectious diseases, which are both characterised by poor commercial potential, as well as differentiating more systematically between costs associated with incremental versus breakthrough innovations.
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib36" ref-type="bibr">36</xref>
</p>
